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Abstract
Multifunctionality or multitasking is the capability of some proteins to execute two or more biochemical functions. The 
objective of this work is to explore the relationship between multifunctional proteins, human diseases and drug targeting. 
The analysis of the proportion of multitasking proteins from the MultitaskProtDB-II database shows that 78% of the proteins 
analyzed are involved in human diseases. This percentage is much higher than the 17.9% found in human proteins in general. 
A similar analysis using drug target databases shows that 48% of these analyzed human multitasking proteins are targets 
of current drugs, while only 9.8% of the human proteins present in UniProt are specified as drug targets. In almost 50% of 
these proteins, both the canonical and moonlighting functions are related to the molecular basis of the disease. A procedure 
to identify multifunctional proteins from disease databases and a method to structurally map the canonical and moonlighting 
functions of the protein have also been proposed here. Both of the previous percentages suggest that multitasking is not a rare 
phenomenon in proteins causing human diseases, and that their detailed study might explain some collateral drug effects.
Keywords Multitasking proteins · Human diseases · Protein function · Drug targets
1 Introduction
The aim of this work was to analyse the link between moon-
lighting proteins and human diseases, as well as between 
moonlighting proteins and current drug targets. Moonlight-
ing or multitasking proteins are those proteins with two or 
more biochemical functions performed by a single polypep-
tide chain. Wistow and Piatigorsky discovered them three 
decades ago when they demonstrated that lens crystallins 
and some metabolic enzymes were the same protein, even 
doing a completely different function and in distinct cel-
lular localizations [1]. Piatigorsky proposed the term gene 
sharing for these proteins [2]. The term moonlighting was 
used for the first time by Constance Jeffery [3] who intended 
to reach a more restrictive definition, as this term does not 
include the cases of gene fusions. Moonlighting proteins 
present alternative functions, usually related to cellular 
localization, cell type, oligomeric state, concentration of 
cellular ligands, substrates, cofactors, products or post-
translational modifications [2–16]. In many cases, a protein 
uses a combination of these mechanisms to switch between 
functions. In the present work, the different functions of 
multitasking proteins have been labelled as “canonical” or 
“moonlighting”, but this has no biological relevance and 
merely refers to the chronological order of the discovery of 
the biological function, the first being canonical [17]. The 
fact that it is an “archaic” function or a function of “recent” 
acquisition affects some aspects of the function, in relation 
to factors such as the contribution to the pathology. Even the 
fact that some prediction methods, like for example domain 
or motif searches, can easily detect the canonical function, 
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but they have serious problems in finding the moonlighting 
function. For this reason, seems interesting to continue with 
this terminology that, moreover, other authors in the field 
maintain. Nevertheless, there are authors that use Function 
1 and Function 2 instead of canonical and moonlighting 
[18]. In general, moonlighting proteins are experimentally 
revealed by serendipity. We only know a small part of the 
existing moonlighting proteins. As initially written by Jef-
fery [6], this type of proteins “appear to be only the tip of 
the iceberg”.
Several authors have reported a number of moonlighting 
proteins involved in human disease [7–9], but, as far as we 
know, there is not a database combining moonlighting pro-
teins and human diseases. In the present work, it is reported 
the percentage of human moonlighting proteins that are 
involved in diseases or are targets of current drugs. Also, a 
procedure is described to identify putative moonlighting pro-
teins from disease databases. When the three-dimensional 
structure of the protein is available, a method to structurally 
map the canonical and moonlighting functions of the protein 
is also proposed. In some cases, these studies can be com-
bined with the aim of explaining some collateral effects of a 
drug related to this moonlighting protein. It has to be taken 
into account that, although bioinformatics analyses can help 
to suggest which proteins are multifunctional and, in some 
cases, map the two functional sites in the structure of the 
protein, identifying true positives must always be demon-
strated experimentally.
2  Materials and Methods
2.1  Databases
Moonlighting proteins listed in the three currently existing 
databases that contain experimentally determined multitask-
ing proteins have been used. These databases are: Multi-
taskProtDB-II [17], MoonProt 2.0 [18] and MoonDB [19] 
and are accessible at http://walla ce.uab.es/multi task, http://
www.moonl ighti ngpro teins .org and http://tagc.univ-mrs.
fr/MoonD B, respectively. The information present in the 
Human Mendelian Inheritance in Man (OMIM, http://www.
omim.org) [20] database and the Human Gene Mutation 
Database (HGMD, http://www.hgmd.cf.ac.uk) [21] for each 
of the proteins has been carefully inspected. With this strat-
egy, the moonlighting proteins that are involved in human 
diseases were identified. Moreover, the Therapeutic Target 
Database (TTD, ttp://bidd.nus.edu.sg/group/cjttd) [22] and 
the DrugBank Database (http://www.drugb ank.ca) [23] 
have been scanned for relevant information in order to see 
if each of the moonlighting proteins is a drug target. When 
necessary, some important protein characteristics have been 
retrieved from The UniProt Consortium (http://www.UniPr 
ot.org) [24]. If available, the three-dimensional structure of 
the protein has been obtained from The Protein Data Bank 
(http://www.rcsb.org) [25].
Statistical significance of the data obtained from these 
sources was analysed by the ODD ratio. The confidence 
interval (CI) used was of 95%. The ODD ratio is a stand-
ard system to measure the degree of association between 
categorical variables of two states (in our case disease/no-
disease vs. moonlighting/no-moonlighting and druggable/
no-druggable vs. moonlighting/no-moonlighting). In order 
to establish the statistical significance of the observed dif-
ferences the Fisher’s exact test has been calculated using R.
2.2  Prediction of New Moonlighting Protein 
Candidates Using OMIM
With the objective of crossing the information between the 
UniProt and the OMIM databases, this sequential procedure 
has been followed: (a) make a list of UniProt proteins that 
are related to diseases according to the OMIM database and 
the literature (3600 proteins were initially collected); (b) 
remove the disease entries caused by more than one pro-
tein; (c) select only those proteins that cause more than one 
disease; (d) manually review the diseases that are caused 
by each of these proteins and: (d1) select those proteins 
in which the diseases are not related to each other, or (d2) 
select those proteins in which the diseases do not seem to be 
related (this means a different molecular basis) to the canon-
ical function of the putative moonlighting protein. This final 
list should contain entries which can be characterized as 
putative moonlighting proteins (Fig. 1).
2.3  Mapping and Linking Diseases to the Canonical 
or Moonlighting Function
An exhaustive analysis of the literature related to the dis-
eases associated with the human multitasking proteins from 
the MultitaskProtDB-II (S1 Table) was performed. For each 
of these cases, the mechanism of action of the pathology has 
been studied with the aim of relating at a molecular level, the 
disease to the canonical, moonlighting or both functions. In 
some of them, not enough data could be found in the litera-
ture in order to relate the pathology to one of the functions. 
When relevant data exist and to demonstrate this condition 
and try to map the canonical and moonlighting functions in 
the structure of the protein, the use of a combination of dif-
ferent methods has been proposed. If the three-dimensional 
structure of the protein is available, the program PiSite [26] 
can be used, as reported by our group in other studies [27, 
28]. This algorithm searches for proteins with a similar 
three-dimensional structure to the query protein. The results 
should again be manually reviewed and used to find for pro-
tein structures that can explain the disease that is not caused 
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by the canonical function. In these cases, the function done 
by this new protein might be the moonlighting function of 
the original protein. With no three-dimensional structure of 
the protein, protein interaction databases, such as BioGRID 
[29] or IMEX consortium [30], can be used. In this case, we 
can look for proteins that interact with our protein and that 
can explain the disease not related to the canonical func-
tion of the query protein. In addition, this interacting protein 
might have an already-solved three-dimensional structure 
and, therefore, the PiSite method mentioned before can be 
applied again. Beginning with the structure of the puta-
tive moonlighting protein or with the structure of a closely 
related interacting protein, the structural annotations can 
be obtained from the literature and UniProt. This informa-
tion contains the key functional regions and amino acids of 
the protein, which should be used to link these characteris-
tics to the pathological effect of the disease. Finally, these 
important regions should be localized in the structure of the 
protein, verifying that they are in different zones in order to 
map the canonical and moonlighting functions. A schematic 
flow-chart has been created to clearly explain the process 
(Fig. 1). It has to be taken into consideration that in all steps 
of the procedure, a more or less detailed manual inspection 
is required in order to obtain significant results.
Our group has collected by the date 611 multitasking 
proteins. This number of proteins doubles the entries of 
MultitaskProtDB [17] and can be found in S1 Table. The 
results presented here have been calculated in reference to 
this new number.
3  Results and Discussion
3.1  Moonlighting Proteins and Human Diseases
The first analysis performed was to find how many human 
moonlighting proteins are related to known human diseases. 
An exhaustive analysis of the literature related to the dis-
eases associated with the human multitasking proteins of 
the MultitaskProtDB-II (S1 Table) shows that 78% of the 
moonlighting proteins in MultitaskProtDB-II are related to 
diseases. These proteins with a description of their functions 
and the diseases in which they are involved can be seen in 
S2 Table.
Fig. 1  Chart flow representation 
of the process followed to pre-
dict moonlighting proteins using 
OMIM database, structural 
analysis and protein interaction
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The number of human proteins indicated as reviewed 
entries in the UniProt database is 20,168 at the time of the 
study. On the one hand, from the OMIM database we saw 
that only 3600 of these proteins are related to human dis-
eases. This result is clearly significant, as can be seen in the 
S4 Table, and it represents a percentage of 17.85%. On the 
other hand, a set of the currently determined human moon-
lighting proteins was created using the published Multitask-
ProtDBII, which can be found in the S1 Table. As before, 
we checked in OMIM and in the literature if these proteins 
were related with human diseases, and a surprising num-
ber was found that shows that 78% of the analyzed proteins 
are involved in human diseases. This percentage is much 
higher than the 17.85% found in human proteins in gen-
eral. The probabilities that a human-UniProt-protein and a 
human -MultitaskProtDB-protein were involved in a known 
OMIM-disease, were calculated using the ODD ratio. Alto-
gether, these results suggest that moonlighting proteins are 
prone to be involved in human diseases as it is pointed by it 
respective ODD ratios; 16.47 (CI 95% 10.95–25.44) in the 
OMIM analysis being highly significant (Fisher’s exact test 
value; p < 2.2e-16) (See S6 Table).
Some relevant examples of moonlighting proteins that 
are involved in human diseases can be seen in Table 1. 
They were identified after crossing the data of OMIM and 
those of HGMD. These examples have been chosen to 
show cases in which the phenotype can be easily attrib-
utable to one of the biological functions of the protein. 
In bold, the putative functions involved in diseases are 
indicated: (C) for those diseases related to the canonical 
function and (M) for those related to the moonlighting 
function. There are some examples where each function 
is related to a different disease (i.e., Fumarate hydratase). 
Sometimes it is difficult to elucidate which function is 
responsible for the disease, suggesting that both functions 
might contribute to the different symptoms (i.e., Hes1 
protein). A huge list of the entire set of 112 moonlight-
ing proteins that are involved in human diseases can be 
found in the S2 Table. A pie-chart representation show-
ing the percentages of moonlighting proteins classified by 
Fig. 2  A1 Distribution of disorders associated with human moon-
lighting proteins and their relative percentages. A2 Distribution of 
disorders associated to human proteins, in general. B1 Functional 
classification of drug-target moonlighting proteins and their relative 
percentages. B2 Functional classification of drug-target in general, 
and their relative percentages
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type of disease can be seen in Fig. 2A1. These results 
could be compared with Fig. 2A2 that shows the same data 
but related to the entire set of human proteins involved 
in diseases according to Uniprot [24]. Two recent works 
belonging to Brun’s group predict 3% of the human inter-
actome correspond to moonlighting proteins. They also 
say that these proteins are significantly involved in more 
than one disease or comorbidity [19, 31]. Fourteen of their 
set of predicted human moonlighting proteins can be found 
in our list of moonlighting proteins involved in human 
diseases (S2 Table). It has to be considered that our list 
was only made up of experimentally demonstrated mul-
titasking proteins, while a number of the moonlighting 
proteins of Brun’s group’s studies correspond to predicted 
moonlighting proteins [32]. The above results imply that 
human moonlighting proteins are significantly associated 
to human diseases compared to non-moonlighting ones.
Table 1  Examples of moonlighting proteins involved in human diseases and drug targets
C Disease related to canonical function, M Disease related to moonlighting function
*Entries are linked to the corresponding information
Protein name (*) Canonical function Moonlighting function Disease Molecular process 
reference (*)
Drug targets (*)
Cyclooxygenase 1 Prostaglandin G/H 
synthase
Heme-dependent per-
oxidase
(C) Bleeding disorder 
type 12
Brit. J. Haemat. 92: 
212–217, 1996
YES
Gephyrin, protein 
anchor
Microtubule-associated 
protein
Synthesis of molybde-
num cofactor (MoCo)
(M) Molybdenum 
cofactor deficiency C
Am J Hum Genet. 2001 
Jan;68(1):208–13
YES
Ribosomal S3 protein Ribosomal protein DNA repair (M) Colon adenocarci-
nomas
https ://doi.
org/10.1016/j.
tig.2014.06.003
NO
Succinyl-coA syn-
thetase
Succinyl-CoA syn-
thetase
Mitochondrial DNA 
maintenance
(M) Mitochondrial 
DNA depletion syn-
drome 9 (encephalo-
myopathic type)
J. Med. Genet. 47: 
670–676, 2010
YES
Fumarate hydratase TCA cycle Tumor suppressor (C) Fumarase defi-
ciency
(M) Leiomyomato-
sis with Renal cell 
cancer
Oncogene. 2015 Mar 
19;34(12):1475–86
NO
ERCC2—TFIIH DNA helicase
DNA repair damaged 
by exposure to ultra-
violet light
It is also a subunit of 
TFIIH, a basal tran-
scription factor
(C) Xeroderma pig-
mentosum
(C) Cerebrooculo faci-
oskeletal syndrome 2
- Mutat Res. 1992 
Mar;273(2):193–202
- Am. J. Hum. Genet. 
69: 291–300, 2001
NO
Alpha-crystallin A 
chain
Lens crystallin Heat-shock protein (C) Cataract
(M) Autoimmune 
diseases
(C) Uveitis
Biomed Pap Med 
Fac Univ Palacky 
Olomouc Czech 
Repub. 2005 
Dec;149(2):243–9
YES
Hes 1 protein Transcriptional repres-
sor
It is able to induce 
the activation of the 
NF-kB pathway in T 
Cell Leukemia
(M) Leukemia, 
myeloid/lymphoid or 
mixed-lineage
Cancer Cell. 2004 
Sep;6(3):203–8
NO
PIAS1 Inhibition of activated 
STAT 
Activation of p53 (M) Cancer Cold Spring Harb Per-
spect Biol. 2009 Nov; 
1(5): a001883
NO
Phosphoglucose 
isomerase
Glycolysis Neuroleukin, differen-
tiation and maturation 
factor/nerve growth 
factor/stimulation 
of cell migration/
implantation factor/
modulator of tumor 
progression and a 
target for cancer 
therapy/sperm surface 
antigen
(C) Hemolytic ane-
mia PGI deficiency
(C) Angiogenesis in 
cancer
- Harefuah. 1994 Jun 
15;126(12):699–702, 
764, 763
- Cancer Res 
2003;63:242–249
YES
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3.2  Prediction of Putative New Moonlighting 
Protein Candidates Using OMIM
In general, moonlighting proteins are experimentally 
revealed by serendipity. Thus, as far as possible, it would be 
very interesting identifying them bioinformatically. Several 
attempts to bioinformatically predict multitasking proteins 
have been proposed by the teams of Brun [19, 32], Kihara 
[33–35] and ours [27, 28, 35–37]. One interesting question 
that occurred to us is whether human genetic-disease data-
bases, such as OMIM, could be a useful resource to find 
moonlighting proteins. A manual inspection of human dis-
ease databases was started to disclose some putative moon-
lighting proteins and, moreover, to try to suggest the molec-
ular basis of the associated disease. Table 2 shows some 
examples of the prediction of putative moonlighting proteins 
present in the OMIM database. It has to be considered that 
the data of protein–protein interaction (PPI) databases and 
the use of the structure comparison tool PiSite can help in 
explaining the unexpected relation with the canonical/moon-
lighting function and the associated disease. For example, in 
the case of the Fanconi anemia group J protein (Q9BX63), 
PPI database searches show that this protein interacts with 
DNA repair proteins but also with the breast cancer protein 
BRC1. Another example is the calcium-independent phos-
pholipase A2 (O60733), in which the canonical function of 
the protein is related to fatty acid metabolism, but it seems to 
be also involved in brain neurodegenerative diseases. Moreo-
ver, a PPI analysis shows a relation between this protein and 
BAG, a protein involved in apoptosis and cell survival. What 
is more, using PiSite, we found whose structure is similar 
to the apoptosis protein caspase-2. More examples on how 
moonlighting proteins can be predicted using disease data-
bases, together with structural and interactomics analyses 
are shown in Table 2.
An intriguing question is whether the mutants of the 
interaction partners of a disease-related moonlighting pro-
tein can also be the cause of the same, or at least very simi-
lar, pathology. This idea strongly reinforces the involvement 
of these mutants in the ailment. Regarding this issue, there 
are some examples in Table 2, such as 3-hydroxyacyl-CoA 
dehydrogenase. This protein is involved in a mental retar-
dation disorder and its interaction partner, the amyloid beta 
A4 protein mutant, is involved in two cerebral-related dis-
eases such as Alzheimer and cerebral angiopathy. Addition-
ally, as mentioned in the previous paragraph, the interac-
tion of phospholipase A2 with BRC1 is a good example 
of two partner mutants causing the same disease as that of 
the predicted moonlighting protein. Otherwise, interaction 
partners involved in different diseases can be found, sug-
gesting that the predicted moonlighting protein may partici-
pate in another as yet unassociated disease. An example of 
this case is the Alpha-aminoadipic semialdehyde synthase 
(Q9UDR5), which presents two cancer-related interaction 
partners: the Myc proto-oncogene protein and the Telomeric 
repeat-binding factor 2.
In summary, it can be said that the prediction of moon-
lighting proteins using OMIM and HGMD databases can 
improve our knowledge at a molecular level of the clinical 
basis of a number of diseases. Further applications of all 
of these studies might help to revisit and reinterpret, some 
human disease phenotypes, generating new therapeutic 
strategies. Moreover, some drug off-side effects might be 
explained [38].
3.3  A Number of Moonlighting Proteins are Drug 
Targets
Current human clinics require identifying the molecular 
basis of a disease and designing the proper therapy for it. 
In most of the cases the therapeutic process requires the use 
of drugs as the main or the complementary treatment. We 
have checked to what extent human moonlighting proteins 
are known targets of current drugs (which represent a small 
and biased set of the potential universe of the druggable 
genome) [39].
Something very curious is that 48% of the human moon-
lighting proteins are current drug targets, while only 9.8% of 
the human proteins present in UniProt are specified as drug 
targets. These calculations were performed as explained in 
the paragraph “Moonlighting proteins and human diseases”, 
but here we took into consideration the 1969 human proteins 
being drug targets present in TTD and DrugBank databases 
[22, 23]. This result is again clearly significant as can be 
seen in the S5 Table. Furthermore, the probabilities that a 
human -UniProt- protein and a human -MultitaskProtDB- 
protein are drug targets listed in TTD and DrugBank data-
bases, were calculated using the ODD Ratio, observing an 
increased ratio of the proportion of druggble proteins 8.49 
(CI 95% 5.99–12.00) in the moonlighting subset, being 
this difference highly significant (Fisher’s exact test value; 
p < 2.2e-16) (See S6 Table).
These calculations and the percentages above highlight 
the interest of moonlighting proteins for gaining insight 
into the molecular basis of genetic-based diseases and for 
rational drug-design upon target identification.
In the last column of Table 1, some examples of those 
related current drugs can be seen following the corre-
sponding link. In S3 Table, the entire set of 68 moonlight-
ing proteins currently identified as drug targets, with the 
corresponding references to the human diseases and drug 
databases, are listed. Figure 2B1 shows a pie-chart repre-
sentation with the percentages of the moonlighting proteins 
that are drug targets classified by functional classes. These 
results could be compared with Fig. 2B2 that shows the same 
data, but related to the entire set of human proteins which 
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are current drug-targets, according to DrugBank database 
[23]. Considering that many diseases involve moonlighting 
proteins, this should also be the same for the protein drug 
targets. Even so, this should not be as simple as it seems. 
“Druggable” does not mean being a drug target because tar-
gets of current drugs represent only successful cases [40]. 
Moreover, it is well known that many non-druggable targets 
exist. It has to be considered that Drews [39] estimated the 
number of potential drug targets as being between 5000 and 
10,000.
Those two stated categories, human disease involvement 
and drug targets, do not appear mutually-exclusive, but in 
our analysis we have used the data of TDT and DrugBank 
databases, which are accepted to be of true drug targets. 
However, there might be information of several hidden tar-
gets in these databases, both for some specific proteins or 
from entire biochemical pathways. It is also true that a num-
ber of drugs can target proteins that, as far as known in the 
present state of the art, are not directly involved in diseases, 
thus contributing to mechanisms such as polypharmacol-
ogy, off-target effects, etc. In a certain number of cases, 
these proteins are not druggable because they are involved 
in such number of pathways that the effect of the putative 
drug would be even deleterious. The biochemical and phar-
macokinetic/pharmacodynamics mechanisms involved in 
these situations, are frequently disclosed with further deeper 
studies. Network pharmacology is an area now growing dra-
matically and, in fact, the procedure described here to map 
the different diseases and putative targets in a protein could 
contribute to gaining insight into the question raised by the 
reviewer. For example, the disclosing of a moonlighting, 
function can suggest new biochemical pathways involved in 
the disease that were previously hidden.
This 48% of human moonlighting proteins being drug 
targets, together with the fact that 78% of the OMIM genes 
correspond to moonlighting proteins, supports the opin-
ion shared by many authors that moonlighting is not a rare 
phenomenon and, therefore, many human proteins would 
be multitasking. In a previous paragraph, the inspection of 
disease gene databases in order to disclose multitasking pro-
teins has been suggested, and we also suggest mining moon-
lighting proteins for drug target-screening. One interesting 
question is whether human genetic-disease databases, such 
as OMIM, could be a useful resource to find moonlighting 
proteins, and whether they relate with pathologies.
3.4  Mapping the Canonical and Moonlighting 
Functions
Generally, the discovery of a moonlighting protein is 
reported without linking each function to a specific domain 
of the protein. Even one of the top moonlighting proteins, 
glyceraldehyde 3-phosphate dehydrogenase, has not been 
functionally mapped (except for its canonical function). 
Therefore, it would be very useful to localize each function, 
as far as possible, in the sequence/structure of the protein.
In our previous work on the bioinformatically prediction 
of multitasking proteins, we have suggested using some 
modelling programs to assign specific regions in the struc-
ture if this information is available [27, 28]. The method 
that was proposed to map the canonical and moonlighting 
functions in the structure of the protein (see Materials and 
Methods section), has been applied to the moonlighting 
protein Fumarase hydratase as an example (protein present 
in Table 1). This protein is associated with the fumarase 
deficiency (FD) and hereditary leiomyomatosis plus renal 
cell cancer (HLRCC) diseases. The UniProt database reports 
protein mutations involved in these diseases. Figure 3 shows 
the 3D structure of the tetramer as well as the mutations 
related to FD and HLRCC, which are depicted in red and 
blue, respectively. In yellow, the mutations associated with 
both diseases are highlighted. This picture clearly shows 
that the canonical function, which is related to FD, is in 
the center of the tetramer, while the moonlighting function, 
which is related to HLRCC, is in a different protein region. 
The structure and amino acid mutants strongly suggests the 
molecular basis of the disease, because these mutations 
seem to perturb the interaction and formation of the cor-
rect tetramer, which in turn can change indirectly, in certain 
degree, the precise positioning of the amino acids of the 
active center, reducing its activity.
As shown in the above examples, the mapping of each 
function on the 3D structure of a multitasking protein might 
be useful for the understanding of its normal and pathologi-
cal functions.
4  Conclusions
In summary, the fact that 78% of moonlighting proteins are 
involved in human diseases and 48% of them are targets of 
current drugs, suggests that moonlighting is not a rare phe-
nomenon in proteins causing human diseases, and that their 
detailed study might explain some collateral drug effects.
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